Filing Flows › Bio-Rad Laboratories (BIO) › Q2 2026 › vs Q1 2026
Bio-Rad Laboratories (BIO) Q2 2026 vs Q1 2026 (quarter over quarter)
Bio-Rad Laboratories's revenue rose $58.9M (+10%) from $592M in Q1 2026 to $651M in Q2 2026. The biggest changes: Clinical Diagnostics +$35.4M (+10%); Life Science +$23.5M (+10%). Gross margin 53.1% against 52.3% (+0.9 pts).
Bio-Rad Laboratories, Q2 2026: revenue $651M (-0.1% year over year), operating margin 11.2%, net earnings $371M, operating cash flow $98.7M. The chart draws each line against Q1 2026, the increases inside each band.
Margins
| Q2 2026 | Q1 2026 | Change | |
|---|---|---|---|
| Gross margin | 53.1% | 52.3% | +0.9 pts |
| Operating margin | 11.2% | 5.8% | +5.4 pts |
| Net margin | 57.1% | -89.0% | +146.1 pts |
| Free cash flow margin | 10.2% | 13.2% | -2.9 pts |
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Clinical Diagnostics | $399M | $364M | $35.4M | +10% |
| Life Science | $252M | $228M | $23.5M | +10% |
| Revenue | $651M | $592M | $58.9M | +10% |
| Gross profit | $346M | $309M | $36.4M | +12% |
| Cost of revenue | $305M | $283M | $22.5M | +8% |
| Other income, net | $470M | −$724M | $1.2B | — |
| Operating profit | $72.6M | $34.1M | $38.5M | +113% |
| Operating expenses | $273M | $275M | −$2.1M | -0.8% |
| Pre-tax earnings | $542M | −$690M | $1.2B | — |
| Research & development | $61.2M | $62.9M | −$1.7M | -3% |
| SG&A | $212M | $212M | −$400K | -0.2% |
| Net earnings | $371M | −$527M | $898M | — |
| Income tax | $171M | −$163M | $333M | — |
| Share-based compensation | $14.5M | $15.0M | −$500K | -3% |
| Working capital & other | $287M | −$620M | $907M | — |
| Operating cash flow | $98.7M | $108M | −$9.4M | -9% |
| Free cash flow (OCF − capex) | $66.7M | $78.1M | −$11.4M | -15% |
| Capital expenditures | $32.0M | $30.0M | $2.0M | +7% |
Questions
How much did Bio-Rad Laboratories's revenue grow quarter over quarter in Q2 2026?
Bio-Rad Laboratories's revenue rose $58.9M (+10%) from $592M in Q1 2026 to $651M in Q2 2026.
What drove Bio-Rad Laboratories's revenue change in Q2 2026?
Clinical Diagnostics +$35.4M (+10%); Life Science +$23.5M (+10%).